Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 508

1.

PathTracer: High-sensitivity detection of differential pathway activity in tumours.

Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD.

Sci Rep. 2019 Nov 8;9(1):16332. doi: 10.1038/s41598-019-52529-3.

2.

Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation.

Mason B, Flach S, Teixeira FR, Manzano Garcia R, Rueda OM, Abraham JE, Caldas C, Edwards PAW, Laman H.

Cell Mol Life Sci. 2019 Sep 27. doi: 10.1007/s00018-019-03306-y. [Epub ahead of print]

PMID:
31560077
3.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.

Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries Schultink A, Bernards R, Saura C, Gallagher W, Cortès J, Caldas C, Linn SC.

Clin Cancer Res. 2019 Aug 22. doi: 10.1158/1078-0432.CCR-19-0508. [Epub ahead of print]

PMID:
31439579
4.

BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.

Walsh L, Haley KE, Moran B, Mooney B, Tarrant F, Madden SF, Di Grande A, Fan Y, Das S, Rueda OM, Dowling CM, Varešlija D, Chin SF, Linn S, Young LS, Jirström K, Crown JP, Bernards R, Caldas C, Gallagher WM, O'Connor DP, Ní Chonghaile T.

Clin Cancer Res. 2019 Aug 13. doi: 10.1158/1078-0432.CCR-19-0713. [Epub ahead of print]

PMID:
31409615
5.

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

McDonald BR, Contente-Cuomo T, Sammut SJ, Odenheimer-Bergman A, Ernst B, Perdigones N, Chin SF, Farooq M, Mejia R, Cronin PA, Anderson KS, Kosiorek HE, Northfelt DW, McCullough AE, Patel BK, Weitzel JN, Slavin TP, Caldas C, Pockaj BA, Murtaza M.

Sci Transl Med. 2019 Aug 7;11(504). pii: eaax7392. doi: 10.1126/scitranslmed.aax7392.

PMID:
31391323
6.

Hospitalization of the aged due to stroke: An ecological perspective.

Carlos MJ, Cavaletti ACL, Caldas CP.

PLoS One. 2019 Aug 7;14(8):e0220833. doi: 10.1371/journal.pone.0220833. eCollection 2019.

7.

Value-based medicine and palliative care: how do they converge?

Sampaio SGDSM, Motta LBD, Caldas CP.

Expert Rev Pharmacoecon Outcomes Res. 2019 Oct;19(5):509-515. doi: 10.1080/14737167.2019.1651645. Epub 2019 Aug 7. Review.

PMID:
31370715
8.

Multi-part quality evaluation of a customized mobile application for monitoring elderly patients with functional loss and helping caregivers.

Costa Stutzel M, Filippo MP, Sztajnberg A, da Costa RMEM, Brites ADS, da Motta LB, Caldas CP.

BMC Med Inform Decis Mak. 2019 Jul 22;19(1):140. doi: 10.1186/s12911-019-0839-3.

9.

Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.

Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M.

EMBO Mol Med. 2019 Jul;11(7):e9982. doi: 10.15252/emmm.201809982. Epub 2019 May 24.

10.

EN1 Is a Transcriptional Dependency in Triple-Negative Breast Cancer Associated with Brain Metastasis.

Peluffo G, Subedee A, Harper NW, Kingston N, Jovanović B, Flores F, Stevens LE, Beca F, Trinh A, Chilamakuri CSR, Papachristou EK, Murphy K, Su Y, Marusyk A, D'Santos CS, Rueda OM, Beck AH, Caldas C, Carroll JS, Polyak K.

Cancer Res. 2019 Aug 15;79(16):4173-4183. doi: 10.1158/0008-5472.CAN-18-3264. Epub 2019 Jun 25.

PMID:
31239270
11.

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.

Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.

Cancer Res. 2019 Aug 15;79(16):4258-4270. doi: 10.1158/0008-5472.CAN-18-3835. Epub 2019 Jun 18.

PMID:
31213465
12.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators.

Lancet. 2019 Jun 29;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6. Epub 2019 Jun 6.

13.

Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis.

Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, Henriques A, Viñas E, Prieto C, Sánchez-Muñoz L, Caldas C, Mayado A, Matito A, Dasilva-Freire N, Orfao A, García-Montero AC.

Blood. 2019 Aug 1;134(5):456-468. doi: 10.1182/blood.2018886507. Epub 2019 May 31.

PMID:
31151985
14.

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C.

Nat Commun. 2019 May 30;10(1):2433. doi: 10.1038/s41467-019-10456-x.

15.

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.

De Mattos-Arruda L, Sammut SJ, Ross EM, Bashford-Rogers R, Greenstein E, Markus H, Morganella S, Teng Y, Maruvka Y, Pereira B, Rueda OM, Chin SF, Contente-Cuomo T, Mayor R, Arias A, Ali HR, Cope W, Tiezzi D, Dariush A, Dias Amarante T, Reshef D, Ciriaco N, Martinez-Saez E, Peg V, Ramon Y Cajal S, Cortes J, Vassiliou G, Getz G, Nik-Zainal S, Murtaza M, Friedman N, Markowetz F, Seoane J, Caldas C.

Cell Rep. 2019 May 28;27(9):2690-2708.e10. doi: 10.1016/j.celrep.2019.04.098.

16.

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.

Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA.

Br J Cancer. 2019 Jun;120(12):1129-1136. doi: 10.1038/s41416-019-0486-6. Epub 2019 May 22.

PMID:
31114020
17.

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips E, Severson T, van de Ven M, Brambillasca C, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler R, Linn S, Jonkers J.

Clin Cancer Res. 2019 Jul 15;25(14):4351-4362. doi: 10.1158/1078-0432.CCR-18-4024. Epub 2019 Apr 29.

PMID:
31036541
18.

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.

Abubakar M, Figueroa J, Ali HR, Blows F, Lissowska J, Caldas C, Easton DF, Sherman ME, Garcia-Closas M, Dowsett M, Pharoah PD.

Mod Pathol. 2019 Sep;32(9):1244-1256. doi: 10.1038/s41379-019-0270-4. Epub 2019 Apr 11.

19.

Usefulness of Omalizumab and Sting Challenge Test in Hymenoptera Venom Allergy and Mastocytosis.

González-de-Olano D, Padial-Vilchez MA, Núñez-Acevedo B, de-Calzada-Bustingorri MP, de-Andrés-Martín A, Caldas C, Piris-Villaespesa M, de-la-Hoz-Caballer B.

J Investig Allergol Clin Immunol. 2019;29(4):318-320. doi: 10.18176/jiaci.0395. Epub 2019 Apr 8. No abstract available.

20.

T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.

Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L.

Ann Oncol. 2019 Mar 29. pii: mdz112. doi: 10.1093/annonc/mdz112. [Epub ahead of print]

PMID:
30924846
21.

Cancer Treatment in the Genomic Era.

Doherty GJ, Petruzzelli M, Beddowes E, Ahmad SS, Caldas C, Gilbertson RJ.

Annu Rev Biochem. 2019 Jun 20;88:247-280. doi: 10.1146/annurev-biochem-062917-011840. Epub 2019 Mar 22.

PMID:
30901264
22.

PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer.

Cox OT, Edmunds SJ, Simon-Keller K, Li B, Moran B, Buckley NE, Bustamante-Garrido M, Healy N, O'Flanagan CH, Gallagher WM, Kennedy RD, Bernards R, Caldas C, Chin SF, Marx A, O'Connor R.

Cancer Res. 2019 May 15;79(10):2619-2633. doi: 10.1158/0008-5472.CAN-18-2787. Epub 2019 Mar 18.

PMID:
30885980
23.

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin JL, Callari M, Batra R, Pereira B, Bruna A, Ali HR, Provenzano E, Liu B, Parisien M, Gillett C, McKinney S, Green AR, Murphy L, Purushotham A, Ellis IO, Pharoah PD, Rueda C, Aparicio S, Caldas C, Curtis C.

Nature. 2019 Mar;567(7748):399-404. doi: 10.1038/s41586-019-1007-8. Epub 2019 Mar 13.

24.

Genome-wide association study of germline variants and breast cancer-specific mortality.

Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Brenner H, Brentnall A, Brinton L, Broberg P, Brock IW, Brucker SY, Burwinkel B, Caldas C, Caldés T, Campa D, Canzian F, Carracedo A, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Cheng TD, Chin SF, Clarke CL; NBCS Collaborators, Cordina-Duverger E, Couch FJ, Cox DG, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dunn JA, Dunning AM, Durcan L, Dwek M, Earl HM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, Gago-Dominguez M, Galle E, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Georgoulias V, Giles GG, Glendon G, Goldgar DE, González-Neira A, Alnæs GIG, Grip M, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hankinson S, Harkness EF, Harrington PA, Hart SN, Hartikainen JM, Hein A, Hillemanns P, Hiller L, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Janni W, John EM, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kabisch M, Kaczmarek K, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kitahara CM, Knight JA, Ko YD, Koppert LB, Kosma VM, Kraft P, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Li L, Lindblom A, Lindström S, Linet M, Lissowska J, Lo WY, Loibl S, Lubiński J, Lux MP, MacInnis RJ, Maierthaler M, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Mavroudis D, McLean C, Meindl A, Middha P, Miller N, Milne RL, Moreno F, Mulligan AM, Mulot C, Nassir R, Neuhausen SL, Newman WT, Nielsen SF, Nordestgaard BG, Norman A, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Petridis C, Pinchev M, Prajzendanc K, Prentice R, Presneau N, Prokofieva D, Pylkäs K, Rack B, Radice P, Ramachandran D, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schwentner L, Scott RJ, Scott C, Seynaeve C, Shah M, Simard J, Smeets A, Sohn C, Southey MC, Swerdlow AJ, Talhouk A, Tamimi RM, Tapper WJ, Teixeira MR, Tengström M, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Torres D, Truong T, Turman C, Turnbull C, Ulmer HU, Untch M, Vachon C, van Asperen CJ, van den Ouweland AMW, van Veen EM, Wendt C, Whittemore AS, Willett W, Winqvist R, Wolk A, Yang XR, Zhang Y, Easton DF, Fasching PA, Nevanlinna H, Eccles DM, Pharoah PDP, Schmidt MK.

Br J Cancer. 2019 Mar;120(6):647-657. doi: 10.1038/s41416-019-0393-x. Epub 2019 Feb 21.

25.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K.

Crit Rev Oncol Hematol. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.

PMID:
30771872
26.

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C.

Nat Commun. 2019 Feb 8;10(1):657. doi: 10.1038/s41467-019-08593-4. Erratum in: Nat Commun. 2019 May 30;10(1):2433.

27.

No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study.

Dong J, Gharahkhani P, Chow WH, Gammon MD, Liu G, Caldas C, Wu AH, Ye W, Onstad L, Anderson LA, Bernstein L, Pharoah PD, Risch HA, Corley DA, Fitzgerald RC; Stomach and Esophageal Cancer Study Consortium, Iyer PG, Reid BJ, Lagergren J, Shaheen NJ, Vaughan TL, MacGregor S, Love S, Palles C, Tomlinson I, Gockel I, May A, Gerges C, Anders M, Böhmer AC, Becker J, Kreuser N, Thieme R, Noder T, Venerito M, Veits L, Schmidt T, Schmidt C, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Mayershofer R, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, Jankowski J, Schumacher J, Neale RE, Whiteman DC, Thrift AP.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2227-2235.e1. doi: 10.1016/j.cgh.2019.01.041. Epub 2019 Feb 1.

PMID:
30716477
28.

Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis.

Dasilva-Freire N, Mayado A, Teodosio C, Jara-Acevedo M, Álvarez-Twose I, Matito A, Sánchez-Muñoz L, Caldas C, Henriques A, Muñoz-González JI, García-Montero AC, Sánchez-Gallego JI, Escribano L, Orfao A.

Int J Mol Sci. 2019 Jan 28;20(3). pii: E552. doi: 10.3390/ijms20030552.

29.

The circular RNome of primary breast cancer.

Smid M, Wilting SM, Uhr K, Rodríguez-González FG, de Weerd V, Prager-Van der Smissen WJC, van der Vlugt-Daane M, van Galen A, Nik-Zainal S, Butler A, Martin S, Davies HR, Staaf J, van de Vijver MJ, Richardson AL, MacGrogan G, Salgado R, van den Eynden GGGM, Purdie CA, Thompson AM, Caldas C, Span PN, Sweep FCGJ, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Paradiso A, Eyfjord J, Broeks A, Vincent-Salomon A, Futreal AP, Knappskog S, King T, Viari A, Børresen-Dale AL, Stunnenberg HG, Stratton M, Foekens JA, Sieuwerts AM, Martens JWM.

Genome Res. 2019 Mar;29(3):356-366. doi: 10.1101/gr.238121.118. Epub 2019 Jan 28.

30.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2.

PMID:
30659290
31.

Cancer Core Europe: A translational research infrastructure for a European mission on cancer.

Eggermont AMM, Apolone G, Baumann M, Caldas C, Celis JE, de Lorenzo F, Ernberg I, Ringborg U, Rowell J, Tabernero J, Voest E, Calvo F.

Mol Oncol. 2019 Mar;13(3):521-527. doi: 10.1002/1878-0261.12447. Epub 2019 Feb 2. Review.

32.

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA.

Gao M, Callari M, Beddowes E, Sammut SJ, Grzelak M, Biggs H, Jones L, Boumertit A, Linn SC, Cortes J, Oliveira M, Baird R, Chin SF, Caldas C.

Genome Med. 2019 Jan 4;11(1):1. doi: 10.1186/s13073-018-0611-9.

33.

miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.

Lindholm EM, Leivonen SK, Undlien E, Nebdal D, Git A, Caldas C, Børresen-Dale AL, Kleivi K.

Microrna. 2019;8(2):155-165. doi: 10.2174/2211536608666181206124922.

PMID:
30520388
34.

Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis.

Vervoort SJ, de Jong OG, Roukens MG, Frederiks CL, Vermeulen JF, Lourenço AR, Bella L, Vidakovic AT, Sandoval JL, Moelans C, van Amersfoort M, Dallman MJ, Bruna A, Caldas C, Nieuwenhuis E, van der Wall E, Derksen P, van Diest P, Verhaar MC, Lam EW, Mokry M, Coffer PJ.

Elife. 2018 Dec 3;7. pii: e27706. doi: 10.7554/eLife.27706.

35.

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V.

EMBO Mol Med. 2018 Dec;10(12). pii: e9172. doi: 10.15252/emmm.201809172.

36.

Impact of somatic and germline mutations on the outcome of systemic mastocytosis.

Muñoz-González JI, Jara-Acevedo M, Alvarez-Twose I, Merker JD, Teodosio C, Hou Y, Henriques A, Roskin KM, Sanchez-Muñoz L, Tsai AG, Caldas C, Matito A, Sánchez-Gallego JI, Mayado A, Dasilva-Freire N, Gotlib JR, Escribano L, Orfao A, García-Montero AC.

Blood Adv. 2018 Nov 13;2(21):2814-2828. doi: 10.1182/bloodadvances.2018020628.

37.

Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century.

Calvo F, Apolone G, Baumann M, Caldas C, Celis JE, de Lorenzo F, Ernberg I, Ringborg U, Rowell J, Tabernero J, Voest E, Eggermont A.

Eur J Cancer. 2018 Nov;103:155-159. doi: 10.1016/j.ejca.2018.08.023. Epub 2018 Sep 18.

PMID:
30241002
38.

Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients.

Risberg B, Tsui DWY, Biggs H, Ruiz-Valdepenas Martin de Almagro A, Dawson SJ, Hodgkin C, Jones L, Parkinson C, Piskorz A, Marass F, Chandrananda D, Moore E, Morris J, Plagnol V, Rosenfeld N, Caldas C, Brenton JD, Gale D.

J Mol Diagn. 2018 Nov;20(6):883-892. doi: 10.1016/j.jmoldx.2018.07.005. Epub 2018 Aug 28.

39.

SOX4 can redirect TGF-β-mediated SMAD3-transcriptional output in a context-dependent manner to promote tumorigenesis.

Vervoort SJ, Lourenço AR, Tufegdzic Vidakovic A, Mocholi E, Sandoval JL, Rueda OM, Frederiks C, Pals C, Peeters JGC, Caldas C, Bruna A, Coffer PJ.

Nucleic Acids Res. 2018 Oct 12;46(18):9578-9590. doi: 10.1093/nar/gky755.

40.

Taking the responsibility in dementia care: A concept analysis about facticity.

Caldas CP, Berterö C.

Nurs Open. 2018 Jun 1;5(3):310-316. doi: 10.1002/nop2.162. eCollection 2018 Jul.

41.

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.

Dev H, Chiang TW, Lescale C, de Krijger I, Martin AG, Pilger D, Coates J, Sczaniecka-Clift M, Wei W, Ostermaier M, Herzog M, Lam J, Shea A, Demir M, Wu Q, Yang F, Fu B, Lai Z, Balmus G, Belotserkovskaya R, Serra V, O'Connor MJ, Bruna A, Beli P, Pellegrini L, Caldas C, Deriano L, Jacobs JJL, Galanty Y, Jackson SP.

Nat Cell Biol. 2018 Aug;20(8):954-965. doi: 10.1038/s41556-018-0140-1. Epub 2018 Jul 18.

42.

Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.

Sonbul SN, Aleskandarany MA, Kurozumi S, Joseph C, Toss MS, Diez-Rodriguez M, Nolan CC, Mukherjee A, Martin S, Caldas C, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Nov;31(11):1675-1682. doi: 10.1038/s41379-018-0092-9. Epub 2018 Jun 28.

43.

Family caregiver of older adults and Cultural Care in Nursing care.

Couto AMD, Caldas CP, Castro EAB.

Rev Bras Enferm. 2018 May;71(3):959-966. doi: 10.1590/0034-7167-2017-0105. Portuguese, English.

44.

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.

Tsui DWY, Murtaza M, Wong ASC, Rueda OM, Smith CG, Chandrananda D, Soo RA, Lim HL, Goh BC, Caldas C, Forshew T, Gale D, Liu W, Morris J, Marass F, Eisen T, Chin TM, Rosenfeld N.

EMBO Mol Med. 2018 Jun;10(6). pii: e7945. doi: 10.15252/emmm.201707945.

45.

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

Xue Z, Vis DJ, Bruna A, Sustic T, van Wageningen S, Batra AS, Rueda OM, Bosdriesz E, Caldas C, Wessels LFA, Bernards R.

Cell Res. 2018 Jul;28(7):719-729. doi: 10.1038/s41422-018-0044-4. Epub 2018 May 24.

46.

αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.

de Groot JS, Ratze MA, van Amersfoort M, Eisemann T, Vlug EJ, Niklaas MT, Chin SF, Caldas C, van Diest PJ, Jonkers J, de Rooij J, Derksen PW.

J Pathol. 2018 Aug;245(4):456-467. doi: 10.1002/path.5099. Epub 2018 Jun 20.

47.

Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element.

Cho SW, Xu J, Sun R, Mumbach MR, Carter AC, Chen YG, Yost KE, Kim J, He J, Nevins SA, Chin SF, Caldas C, Liu SJ, Horlbeck MA, Lim DA, Weissman JS, Curtis C, Chang HY.

Cell. 2018 May 31;173(6):1398-1412.e22. doi: 10.1016/j.cell.2018.03.068. Epub 2018 May 3.

48.

Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.

Fewings E, Larionov A, Redman J, Goldgraben MA, Scarth J, Richardson S, Brewer C, Davidson R, Ellis I, Evans DG, Halliday D, Izatt L, Marks P, McConnell V, Verbist L, Mayes R, Clark GR, Hadfield J, Chin SF, Teixeira MR, Giger OT, Hardwick R, di Pietro M, O'Donovan M, Pharoah P, Caldas C, Fitzgerald RC, Tischkowitz M.

Lancet Gastroenterol Hepatol. 2018 Jul;3(7):489-498. doi: 10.1016/S2468-1253(18)30079-7. Epub 2018 Apr 27.

49.

High USP6NL Levels in Breast Cancer Sustain Chronic AKT Phosphorylation and GLUT1 Stability Fueling Aerobic Glycolysis.

Avanzato D, Pupo E, Ducano N, Isella C, Bertalot G, Luise C, Pece S, Bruna A, Rueda OM, Caldas C, Di Fiore PP, Sapino A, Lanzetti L.

Cancer Res. 2018 Jul 1;78(13):3432-3444. doi: 10.1158/0008-5472.CAN-17-3018. Epub 2018 Apr 24.

50.

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.

Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.

Supplemental Content

Loading ...
Support Center